Home > Press > Nanotechnology Gold Rush Yields Crowded, Entangled Patents
New report from Lux Research and Foley & Lardner LLP assesses 1,084 nanotech patents; finds that nanotech winners and losers could be decided by courts and not consumers
Nanotechnology Gold Rush Yields Crowded, Entangled Patents
New York, NY | April 21, 2005
A gold-rush mentality has taken hold in nanotechnology, and patents are the precious resource being hoarded. As of late March 2005, 3,818 U.S. nanotechnology patents had been issued with another 1,777 patent applications awaiting judgment. But entrepreneurs’ ability to turn their patents into cash may be limited by crowded claims that overlap with one another, according to a new report from Lux Research entitled “The Nanotech Intellectual Property Landscape.” The report was developed in partnership with patent attorneys in the nanotechnology practice at law firm Foley & Lardner LLP.
“Nanotech researchers worldwide are steadily filing patents in the hopes of creating ‘tollbooths’ for future products incorporating nanomaterials,” said Lux Research Vice President of Research Matthew Nordan. “Nanomaterials – the ‘building blocks’ of nanotechnology, like carbon nanotubes and quantum dots – have seen particular focus. Our comprehensive patent review shows that the patent landscape for these materials is complex and fragmented. Because so many patents have been filed relating to nanomaterials, and so many of them seem to overlap, companies that want to use these building blocks in products will be forced to license patents from many different sources in order to do so.”
To analyze the landscape of nanotechnology IP, Lux Research and Foley & Lardner systematically reviewed 1,084 U.S. patents – representing 19,485 claims – that relate to five nanomaterials: 1) dendrimers, 2) quantum dots, 3) carbon nanotubes, 4) fullerenes, and 5) nanowires. The patents were reviewed manually on a claim-by-claim basis; no software automation was used. The team broke down patents for each nanomaterial platform by application and rated them according to how much “white space” remains for new claims and how entangled existing patents look, using a rigorous, quantitative methodology.
The report concludes that:
- Dendrimers pose the biggest question mark, scoring low on white space and freedom from entanglement for all commercially significant applications. A large number of relevant claims have been assigned from pioneer Dow to one start-up company, Dendritic Nanotechnologies.
- Quantum dots have particularly knotty entanglement for general claims that cover the materials themselves and not any specific application. This fact casts doubt on the commercial value of quantum dot IP.
- Carbon nanotube patents look messy in electronics, but promising in energy and healthcare and cosmetics. The common assumption that carbon nanotube patents are both numerous and overlapping across all important application categories is incorrect.
- Fullerenes look relatively unentangled, but crowded with abandoned patents. The good news: Fullerenes show less entanglement than the previous three categories. The bad news: Many patents issued may be useless – inventors have given up on a third of them by failing to pay patent maintenance fees.
- Nanowire patents number few and seem distinct – but Nanosys looms large. Nanowire patents offer a good opportunity to license the most important ones on an exclusive basis without worrying about IP entanglement – so good that start-up Nanosys has already attempted to do it.
"Looking into the future, while some nanotech patent litigation is inevitable, those who have their own patents will have some leverage with which to avoid a self-destructive IP war," said Stephen B. Maebius, chair of the Nanotechnology Industry Team at Foley & Lardner LLP. "The stage is set for a wave of cross-licensing agreements by start-ups, and bundles of IP for specific applications licensed by groups of large corporations. We advise companies filing nanotech patents to go for claims of intermediate scope - not just broad claims - recognizing that the courts might not uphold all broad claims, as has been the case with a number of biotech patents. Firms licensing nanotech IP should define fields of use with great care, given that most nanotech inventions cut across multiple industries and may find commercial applications in diverse fields."
The report and its underlying data set are available immediately to clients of Lux Research’s Nanotechnology Strategies advisory service. For information on how to become a client, contact Steve Mills at (646) 723-0163.
About Lux Research
Lux Research is the world's leading nanotechnology research and advisory firm. We help our clients make better decisions to profit from nanoscale science and technology, tapping into our analysts' unique expertise and unrivaled network. Our clients include top decision makers at large corporations, portfolio managers and analysts at leading financial institutions, CEOs of the most innovative start-ups, and visionary public policy makers. To get connected and for more information, visit www.luxresearchinc.com
About Foley & Lardner LLP
Foley & Lardner LLP is a provider of legal counsel to global companies. The firm's experience encompasses a full range of corporate legal services. Foley & Lardner's attorneys understand today's most complex business issues including corporate governance, securities enforcement, litigation, mergers and acquisitions, intellectual property and IP litigation, labor and employment, and tax. The firm offers total solutions in the nanotechnology, life sciences, automotive, e-business and information technology, energy, financial services, food, health care, insurance, golf and resort services, and sports industries. Our Web site can be found at www.foley.com.
Copyright © Lux Research
If you have a comment, please Contact
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
A sponge-like molecular cage for purification of fullerenes December 15th, 2014
'Trojan horse' proteins used to target hard-to-reach cancers: Scientists at Brunel University London have found a way of targeting hard-to-reach cancers and degenerative diseases using nanoparticles, but without causing the damaging side effects the treatment normally brings December 11th, 2014
Detecting gases wirelessly and cheaply: New sensor can transmit information on hazardous chemicals or food spoilage to a smartphone December 8th, 2014
Green meets nano: Scientists at TU Darmstadt create multifunctional nanotubes using nontoxic materials December 3rd, 2014
Creation of 'Rocker' protein opens way for new smart molecules in medicine, other fields December 18th, 2014
Iranian Researchers Produce Electrical Pieces Usable in Human Body December 18th, 2014
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial December 17th, 2014
Unraveling the light of fireflies December 17th, 2014
Aculon Hires New Business Development Director December 19th, 2014
ORNL microscopy pencils patterns in polymers at the nanoscale December 17th, 2014
Pb islands in a sea of graphene magnetise the material of the future December 16th, 2014
Graphene Applied in Production of Recyclable Electrodes December 13th, 2014
Oregon researchers glimpse pathway of sunlight to electricity: Collaboration with Lund University uses modified UO spectroscopy equipment to study 'maze' of connections in photoactive quantum dots December 19th, 2014
Instant-start computers possible with new breakthrough December 19th, 2014
Aculon Hires New Business Development Director December 19th, 2014
Iranian Scientists Use Nanotechnology to Increase Power, Energy of Supercapacitors December 18th, 2014
Silicon Valley-Based Foresight Valuation Launches STR-IP™, a New Initiative for Startups to Discover the Value of Their Intellectual Property December 18th, 2014
Chemists Fabricate Novel Rewritable Paper: An attractive alternate to regular paper, UC Riverside-developed technology helps address increasing problems in environment and resource sustainability December 2nd, 2014
Dicerna Announces License Agreement with Tekmira to Advance Dicerna’s PH1 Development Program November 17th, 2014
First genetic-based tool to detect circulating cancer cells in blood: NanoFlares light up individual cells if breast cancer biomarker is present November 17th, 2014